Skip to main content
EMBC
NASDAQ Industrial Applications And Services

Embecta Files Owen Mumford Financials: Pro Forma Revenue Hits $1.17B, $180M Debt Draw

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$3.59
Mkt Cap
$215.953M
52W Low
$2.77
52W High
$15.55
52W Position info
30% above low
Off High info
77% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

EMBC sits 30% above its 52-week low of $2.77.

Summary

Embecta filed the required audited financials and pro forma combined statements for its acquisition of Owen Mumford, showing the target's FY2025 revenue of £68.6M and profit of £1.7M, and revealing a $180M debt draw to fund the deal.


Key Events · M&A and Partnerships · EMBC

  • Owen Mumford Financials Disclosed

    Audited FY2025 results show £68.6M turnover, £1.7M profit, and £102.7M net assets. The business was modestly profitable with strong net assets.

  • Pro Forma Combined Financials

    Pro forma combined revenue of $1,172.5M and net income of $75.7M for FY2025, reflecting the acquisition's scale but also the added interest and amortization costs.

  • $180M Debt Draw to Fund Deal

    Embecta drew $180M from its revolving credit facility to pay the upfront cash consideration of £126M ($166.1M) and transaction costs, increasing pro forma interest expense by $11.5M annually.

  • Purchase Price Allocation

    Preliminary allocation assigns $40.5M to intangible assets (12-13 year useful lives), $25.8M to goodwill, and a $19.5M step-up in PP&E. Contingent consideration of up to £50M tied to Aidaptus sales.


Analysis · EMBC · Industrial Applications And Services

This amendment delivers the audited financials of Owen Mumford and the pro forma combined statements that were missing from the original acquisition 8-K. The numbers show Owen Mumford generated £68.6M in revenue and £1.7M in profit for FY2025, with net assets of £102.7M. On a pro forma basis, the combined company would have posted $1.17B in revenue and $75.7M in net income for the same period. The filing also reveals Embecta drew $180M from its revolving credit facility to fund the deal, adding to its already heavy debt load. The purchase price allocation assigns $40.5M to intangibles and $25.8M to goodwill, with up to £50M in earn-outs tied to Aidaptus sales. This fills in the financial picture of a transformative acquisition that closed in May, but the added debt and modest profitability of the target underscore the execution risk.

At the time of this filing, EMBC was trading at $3.59 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $216M. The 52-week trading range was $2.77 to $15.55. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EMBC - Latest Insights

EMBC
Jun 23, 2026, 11:52 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $3.08
Real-time Price: $3.59 info
Change: +$0.515 (+17%) info
Market Cap: $215.953M info
EMBC
May 15, 2026, 9:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.13
Real-time Price: $3.59 info
Change: +$0.465 (+15%) info
Market Cap: $215.953M info
EMBC
May 15, 2026, 9:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.12
Real-time Price: $3.59 info
Change: +$0.4691 (+15%) info
Market Cap: $215.953M info
EMBC
May 05, 2026, 1:31 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.08
Real-time Price: $3.59 info
Change: -$0.485 (-12%) info
Market Cap: $215.953M info
EMBC
May 05, 2026, 6:55 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.78
Real-time Price: $3.59 info
Change: -$4.19 (-54%) info
Market Cap: $215.953M info